AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2024
Feb 21, 2024
30849_dirs_2024-02-21_e88b27c8-9f3b-48d0-9fc8-d22e78982a83.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2024-02-16
Reporting Person: Lee Jennifer Kayden (EVP, Head of North America)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-16 | Common Stock | A | 33750 | — | Acquired | 40602 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-16 | Restricted Stock Units | $ | A | 22000 | Acquired | Common Stock (22000) | Direct | |
| 2024-02-16 | Stock Option (Right to Buy) | $49.23 | A | 67000 | Acquired | 2034-02-15 | Common Stock (67000) | Direct |
Footnotes
F1: The Issuer previously granted the Reporting Person an award of restricted stock units that vest based on the Issuer's satisfaction of certain performance objectives. On February 16, 2024, the Board determined that the performance condition had been satisfied.
F2: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F3: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date.
F4: The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.